Compare
PMGC Holdings Inc. vs Silence Therapeutics plc vs BioXcel Therapeutics, Inc. vs Polomar Health Services, Inc.
| Latest fiscal year | PMGC Holdings Inc. ELAB | Silence Therapeutics plc SLN | BioXcel Therapeutics, Inc. BTAIQ | Polomar Health Services, Inc. PMHS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $590.1K | $559.0K | $642.0K | $648.2K |
| Revenue growth (YoY) | n/a | -98.7% | -71.7% | n/m |
| Gross margin | 31.4% | 61.5% | 74.5% (computed) | 71.0% |
| Operating margin | n/a | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$7.75M | -$88.61M | -$69.90M | -$10.70M |
| EPS (Diluted) | n/a | -$0.63 | -$5.73 | -$0.39 |
| Operating cash flow | -$5.93M | -$62.27M | -$57.62M | -$396.0K |
| Free cash flow | -$6.38M | -$62.33M | -$57.62M | n/a |
| Cash & equivalents | n/a | $11.28M | $28.41M | $132.2K |
| Total assets | $12.87M | $131.44M | $44.92M | $390.0K |
| Total liabilities | $5.03M | $69.14M | $140.38M | $1.61M |
| Shareholders' equity | $7.84M | $62.30M | -$95.46M | -$1.22M |
| Return on year-end equity | -98.9% | -142.2% | n/a | n/a |
| Shares outstanding | 80.7K | 141.70M | 22.33M | 28.02M |
Revenue, most recent five fiscal years
| Fiscal year | PMGC Holdings Inc. | Silence Therapeutics plc | BioXcel Therapeutics, Inc. | Polomar Health Services, Inc. |
|---|---|---|---|---|
| Latest | $590.1K Ended 2025-12-31 | $559.0K Ended 2025-12-31 | $642.0K Ended 2025-12-31 | $648.2K Ended 2025-12-31 |
| 1 year earlier | n/a | $43.26M Ended 2024-12-31 | $2.27M Ended 2024-12-31 | $58.8K Ended 2024-12-31 |
| 2 years earlier | $1.71M Ended 2023-12-31 | $31.64M Ended 2023-12-31 | $1.38M Ended 2023-12-31 | $41.8K Ended 2023-12-31 |
| 3 years earlier | $766.3K Ended 2022-12-31 | $21.66M Ended 2022-12-31 | $375.0K Ended 2022-12-31 | $34.5K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | n/a |